updates on the use of momelotinib for the treatment of mf & clinical trials evaluating this agent
Published 2 years ago • 507 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
1:53
recent updates from the momentum trial and the value of momelotinib for the treatment of mf
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
3:00
the promise of momelotinib in the treatment of myelofibrosis
-
4:25
update on momelotinib for myelofibrosis
-
3:03
an insight into the momentum trial: safety and efficacy of momelotinib for the treatment of mf
-
2:07
the current research on momelotinib for myelofibrosis
-
1:01
clinical outcomes for patients with myelofibrosis after transition from ruxolitinib to momelotinib
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
21:38
drawing the line: the rationale behind blood tube collection order
-
4:49
myelofibrosis - causes, symptoms, diagnosis, treatment, pathology
-
4:10
the management of prefibrotic myelofibrosis
-
2:48
updated results from the momentum trial
-
2:26
assessing the impact of momelotinib on transfusion burden in mf: analysis of simplify-1 & momentum
-
1:52
an update on the use of navtemadlin in myelofibrosis
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:28
momelotinib in 2024: how should this agent be used in mf with anemia?
-
4:48
an insight into the management of cytopenias in mf
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
1:18
novel approaches for the treatment of myelofibrosis: navitoclax ruxolitinib
-
2:20
momentum & the potential impact of approval of momelotinib in myelofibrosis
-
2:53
long-term safety of momelotinib in myelofibrosis: pooled data from three phase iii randomized trials